Suwannakhon Narutchala, Pangeson Tanapat, Seeratanachot Teerapat, Mahingsa Khwanruedee, Pingyod Arunee, Bumrungpakdee Wanwipa, Sanguansermsri Torpong
Discipline of Biology, School of Science.
Discipline of Biochemistry, School of Medical Science.
Hematol Rep. 2019 Sep 18;11(3):8124. doi: 10.4081/hr.2019.8124.
We propose using a modified amplification refractory mutation system real-time polymerase chain reaction (ARMS RTPCR) technique to exclude the invasive prenatal diagnosis for a non-paternally inherited beta thalassemia mutation in couples atrisk for having a baby with CHBT. The ARMS RT-PCR method was performed for 36 at-risk couples by using isolated fetal cell-free DNA from maternal plasma. The modified ARMS RT-PCR primers targeted one of the following paternally inherited beta thalassemia mutation: -28 A→G, CD17 A→T, CD 26 G→A, IVS1-1 G→T and CD 41-42 -CTTT. The method could be successfully employed for NIPST starting with the 7 week of gestation. The results showed that 19 pregnant women were negative for PIBTM (53%). After an on-track and on-time of one year, including postnatal thalassemia blood tests, none of the babies showed symptoms or signs of beta thalassemia disease. We concluded that the modified ARMS RT-PCR method was an accurate, cost-effective and feasible method for use as a NIPST for at-risk couples with the potential of having a baby with CHBT.
我们建议使用改良的扩增阻滞突变系统实时聚合酶链反应(ARMS RTPCR)技术,对有生育患有重型β地中海贫血患儿风险的夫妇,排除非父系遗传的β地中海贫血突变的侵入性产前诊断。通过使用从孕妇血浆中分离的游离胎儿DNA,对36对有风险的夫妇进行了ARMS RT-PCR方法检测。改良的ARMS RT-PCR引物靶向以下父系遗传的β地中海贫血突变之一:-28 A→G、CD17 A→T、CD 26 G→A、IVS1-1 G→T和CD 41-42 -CTTT。该方法从妊娠7周开始即可成功用于无创产前筛查(NIPST)。结果显示,19名孕妇的父系遗传β地中海贫血突变(PIBTM)检测为阴性(53%)。经过一年的随访,包括产后地中海贫血血液检测,没有一个婴儿出现β地中海贫血疾病的症状或体征。我们得出结论,改良的ARMS RT-PCR方法是一种准确、经济有效且可行的方法,可作为有生育患有重型β地中海贫血患儿风险夫妇的无创产前筛查方法。